Julio Cortijo Selected Research

roflumilast N-oxide

8/2014	Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease.
8/2014	Roflumilast N-oxide inhibits bronchial epithelial to mesenchymal transition induced by cigarette smoke in smokers with COPD.
1/2013	Roflumilast inhibits respiratory syncytial virus infection in human differentiated bronchial epithelial cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Julio Cortijo Research Topics

Disease

19	Chronic Obstructive Pulmonary Disease (COPD) 01/2022 - 06/2005
11	Fibrosis (Cirrhosis) 06/2021 - 01/2015
9	Asthma (Bronchial Asthma) 01/2022 - 01/2003
9	Inflammation (Inflammations) 06/2021 - 04/2002
7	Pulmonary Fibrosis (Fibrosing Alveolitis) 06/2021 - 10/2013
7	Respiratory Tract Diseases (Respiratory Tract Disease) 03/2021 - 01/2012
6	Idiopathic Pulmonary Fibrosis 01/2021 - 02/2012
4	Neoplasms (Cancer) 02/2022 - 01/2012
4	Pneumonia (Pneumonitis) 01/2022 - 02/2015
4	Lung Diseases (Lung Disease) 03/2021 - 01/2005
4	Rhinosinusitis 01/2019 - 02/2015
3	Pulmonary Hypertension 01/2018 - 10/2013
3	Hypoxia (Hypoxemia) 01/2018 - 01/2012
3	Necrosis 08/2016 - 06/2008
3	Cardiovascular Diseases (Cardiovascular Disease) 08/2016 - 07/2009
3	Virus Diseases (Viral Diseases) 01/2016 - 09/2011
3	Respiratory Syncytial Virus Infections 01/2016 - 01/2012
3	Infections 01/2013 - 11/2005
3	Ciliary Motility Disorders (Primary Ciliary Dyskinesia) 07/2012 - 05/2010
2	Lung Neoplasms (Lung Cancer) 03/2021 - 01/2021
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 01/2019
2	Cystic Fibrosis (Mucoviscidosis) 01/2021 - 10/2013
2	Nasal Polyps (Nasal Polyp) 03/2017 - 02/2015
2	Nausea 01/2017 - 06/2005
2	Myocardial Infarction 08/2016 - 12/2004
2	Heart Failure 08/2016 - 06/2008
2	Bronchial Spasm 08/2012 - 01/2005
2	Atherosclerosis 11/2007 - 05/2006
2	Respiratory Hypersensitivity 03/2006 - 01/2005
1	Erythema 02/2022
1	Mitochondrial Diseases (Mitochondrial Disease) 12/2021
1	Disease Progression 06/2021
1	Myeloproliferative Disorders (Myeloproliferative Disorder) 06/2021
1	Vascular Remodeling 05/2021
1	Pathologic Processes 03/2021
1	Interstitial Lung Diseases (Interstitial Lung Disease) 03/2021
1	Bacterial Infections (Bacterial Infection) 01/2021

Drug/Important Bio-Agent (IBA)

9	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 01/2005
9	Bleomycin (Blenoxane)FDA LinkGeneric 01/2021 - 10/2013
9	MucinsIBA 01/2021 - 01/2005
7	Phosphodiesterase 4 InhibitorsIBA 01/2017 - 06/2005
6	Proteins (Proteins, Gene)FDA Link 02/2022 - 01/2005
6	Interleukin-8 (Interleukin 8)IBA 01/2022 - 12/2004
6	SmokeIBA 12/2021 - 06/2010
6	RoflumilastIBA 01/2017 - 06/2005
5	LipopolysaccharidesIBA 01/2022 - 06/2008
5	Biomarkers (Surrogate Marker)IBA 06/2021 - 08/2014
5	AntioxidantsIBA 01/2013 - 09/2011
4	Mucin-1 (CA 15-3 Antigen)IBA 03/2021 - 02/2015
4	Muscarinic AntagonistsIBA 01/2019 - 11/2009
3	Protein Isoforms (Isoforms)IBA 05/2021 - 01/2017
3	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2021 - 12/2009
3	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2021 - 05/2012
3	CytokinesIBA 01/2021 - 02/2015
3	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 01/2019 - 08/2014
3	Dexamethasone (Maxidex)FDA LinkGeneric 01/2019 - 02/2015
3	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 01/2017 - 04/2002
3	Messenger RNA (mRNA)IBA 08/2016 - 01/2013
3	roflumilast N-oxideIBA 08/2014 - 01/2013
3	Angiotensin IIIBA 09/2010 - 05/2006
3	Serotonin (5 Hydroxytryptamine)IBA 06/2010 - 01/2005
2	Paclitaxel (Taxol)FDA LinkGeneric 02/2022 - 01/2022
2	Fluticasone (Cutivate)FDA LinkGeneric 01/2022 - 01/2019
2	Janus Kinase InhibitorsIBA 01/2022 - 06/2021
2	Interleukin-6 (Interleukin 6)IBA 06/2021 - 01/2013
2	Pharmaceutical PreparationsIBA 03/2021 - 01/2021
2	LAS190792IBA 01/2019 - 10/2017
2	Small Interfering RNA (siRNA)IBA 11/2018 - 07/2010
2	Vasodilator Agents (Vasodilators)IBA 01/2018 - 01/2016
2	Type 4 Cyclic Nucleotide PhosphodiesterasesIBA 01/2017 - 01/2013
2	aclidinium bromideIBA 11/2016 - 11/2009
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 08/2016 - 01/2012
2	RNA (Ribonucleic Acid)IBA 01/2015 - 01/2013
2	LipidsIBA 01/2014 - 07/2006
2	Nitric Oxide Synthase (NO Synthase)IBA 10/2013 - 06/2010
2	Adenylate KinaseIBA 07/2012 - 05/2010
2	Acetylcysteine (Siran)FDA LinkGeneric 01/2012 - 01/2012
1	Janus KinasesIBA 01/2022
1	Superoxides (Superoxide)IBA 01/2022
1	Monoclonal AntibodiesIBA 06/2021
1	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2021
1	CarcinogensIBA 01/2021
1	Peroxynitrous Acid (Peroxynitrite)IBA 01/2021
1	Peptides (Polypeptides)IBA 01/2021
1	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2021
1	dacomitinibIBA 01/2021
1	DNA (Deoxyribonucleic Acid)IBA 01/2021
1	pirfenidoneIBA 04/2020
1	GO 201IBA 01/2020
1	Calcium-Transporting ATPases (Ca2+ ATPase)IBA 01/2020
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2019
1	Bronchodilator Agents (Bronchodilators)IBA 01/2019
1	AZD-8871IBA 01/2019
1	Adrenergic Receptors (Adrenergic Receptor)IBA 01/2019
1	osimertinibIBA 01/2019
1	OvalbuminIBA 01/2019
1	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 01/2019
1	Serine (L-Serine)FDA Link 01/2019

Therapy/Procedure

7	Therapeutics 01/2021 - 01/2012
2	Parenteral Nutrition 01/2014 - 07/2006